Gene deletion speeds mutation rate.

abstract：UNLABELLED:Knowledge of "actionable" somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic ...

journal_title：Cancer discovery

authors： Wagle N,Berger MF,Davis MJ,Blumenstiel B,Defelice M,Pochanard P,Ducar M,Van Hummelen P,Macconaill LE,Hahn WC,Meyerson M,Gabriel SB,Garraway LA

更新日期：2012-01-01 00:00:00

abstract：:Nuclear hormone receptor targeting suppresses melanoma progression in diverse preclinical models. ...

journal_title：Cancer discovery

authors：

更新日期：2014-05-01 00:00:00

abstract：UNLABELLED:Targeted molecular therapy has yielded remarkable outcomes in certain cancers, but specific therapeutic targets remain elusive for many others. As a result of two independent RNA interference (RNAi) screens, we identified pathway dependence on a member of the Janus-activated kinase (JAK) tyrosine kinase fami...

journal_title：Cancer discovery

authors： Sanda T,Tyner JW,Gutierrez A,Ngo VN,Glover J,Chang BH,Yost A,Ma W,Fleischman AG,Zhou W,Yang Y,Kleppe M,Ahn Y,Tatarek J,Kelliher MA,Neuberg DS,Levine RL,Moriggl R,Müller M,Gray NS,Jamieson CH,Weng AP,Staudt LM

更新日期：2013-05-01 00:00:00

abstract：:Epigenetic regulators, when genomically altered, may become driver oncogenes that mediate otherwise unexplained pro-oncogenic changes lacking a clear genetic stimulus, such as activation of the WNT/β-catenin pathway in melanoma. This study identifies previously unrecognized recurrent activating mutations in the G9a hi...

journal_title：Cancer discovery

authors： Kato S,Weng QY,Insco ML,Chen KY,Muralidhar S,Pozniak J,Diaz JMS,Drier Y,Nguyen N,Lo JA,van Rooijen E,Kemeny LV,Zhan Y,Feng Y,Silkworth W,Powell CT,Liau BB,Xiong Y,Jin J,Newton-Bishop J,Zon LI,Bernstein BE,Fish

更新日期：2020-07-01 00:00:00

abstract：:In the setting of recent exciting clinical results and numerous ongoing trials, Piotrowska and colleagues explore mechanisms of acquired resistance to the mutant-specific EGFR inhibitor rociletinib, and demonstrate that loss of T790M, EGFR amplification, and small-cell transformation are all clinically relevant mechan...

journal_title：Cancer discovery

authors： Ichihara E,Lovly CM

更新日期：2015-07-01 00:00:00

abstract：:A report from the National Academies of Sciences, Engineering, and Medicine lays out 12 recommendations to help scientists decide whether to return research results to study participants and, if they do, how to improve the sharing of information. The most important change the report recommends is harmonizing contradic...

journal_title：Cancer discovery

authors：

更新日期：2018-09-01 00:00:00

abstract：:In the ECHO-202/KEYNOTE-037 and ECHO-204 trials reported at the 2017 Annual Meeting of the American Society of Clinical Oncology, patients with squamous cell carcinoma of the head and neck responded well to the combinations of epacadostat plus pembrolizumab and epacadostat plus nivolumab. An IDO1 inhibitor, epacadosta...

journal_title：Cancer discovery

authors：

更新日期：2017-09-01 00:00:00

abstract：:Metabolic reprogramming enables cancer cell growth, proliferation, and survival. This reprogramming is driven by the combined actions of oncogenic alterations in cancer cells and host cell factors acting on cancer cells in the tumor microenvironment. Cancer cell intrinsic mechanisms activate signal transduction compon...

journal_title：Cancer discovery

authors： Dey P,Kimmelman AC,DePinho RA

更新日期：2021-01-27 00:00:00

abstract：:Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor before its best seller, lenalidomide, faces competition from generics. ...

journal_title：Cancer discovery

authors：

更新日期：2018-03-01 00:00:00

abstract：:In the plasmaMATCH trial, researchers performed circulating tumor DNA testing on patients with advanced breast cancer and matched those with ESR1, HER2, or AKT1 alterations to targeted therapies. Patients with HER2 and AKT1 mutations experienced response rates greater than 22% with durable benefit. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:Gilead Sciences will buy Kite Pharma-and its autologous CAR T-cell technology-for $11.9 billion. The acquisition will help Gilead build its oncology portfolio and boost its revenues. ...

journal_title：Cancer discovery

authors：

更新日期：2017-10-01 00:00:00

abstract：:Asparagine promotes the survival of cancer cells in response to glutamine withdrawal. ...

journal_title：Cancer discovery

authors：

更新日期：2014-11-01 00:00:00

abstract：:Metastasizing tumor cells lose expression of the tumor suppressor PTEN at a much higher rate when they enter the brain compared to other organs, suggesting that the brain's unique microenvironment may prime metastatic cells for aggressive growth, a recent study reports. The findings may have implications for developin...

journal_title：Cancer discovery

authors：

更新日期：2016-01-01 00:00:00

abstract：:Pemigatinib was effective in patients with cholangiocarcinomas with FGFR2 fusions or rearrangements. ...

journal_title：Cancer discovery

authors：

更新日期：2020-05-01 00:00:00

abstract：:New research shows immunotherapy can cause lethal inflammation in both young and aged mice that are obese. Restricting calories in aged mice protected them from toxicity, and giving young obese mice a drug for autoimmune disease prevented the fatal reactions. ...

journal_title：Cancer discovery

authors：

更新日期：2015-01-01 00:00:00

abstract：:The new iRECIST guideline-developed in consultation with academics, drug companies, and regulatory authorities-provides a standardized approach to assessing whether patients' disease improves, stays the same, or worsens in trials of immunotherapeutics, agents that can trigger different response patterns from other kin...

journal_title：Cancer discovery

authors：

更新日期：2017-05-01 00:00:00

abstract：:Preconditioning the immune system with a tetanus/diphtheria toxoid significantly improved the effectiveness of dendritic cell immunotherapy and extended overall survival in a small, randomized study of patients with glioblastoma. ...

journal_title：Cancer discovery

authors：

更新日期：2015-06-01 00:00:00

abstract：:YY1 preferentially occupies active enhancers and promoters and forms dimers to promote DNA looping. ...

journal_title：Cancer discovery

authors：

更新日期：2018-02-01 00:00:00

abstract：:Researchers have developed an antibody-drug conjugate with the potential to treat neuroblastoma. The agent targets ALK, which is found on neuroblastoma cells but not healthy cells, delivering a drug that causes DNA cross-links. Researchers have found that the antibody-drug conjugate kills ALK-expressing cells in vitro...

journal_title：Cancer discovery

authors：

更新日期：2019-06-01 00:00:00

abstract：:A recent study suggests that natural killer (NK) cells may play an important role in antitumor response to immune checkpoint inhibitors. Researchers used mouse models to show that NK cells respond to PD-1 and PD-L1 inhibitors, information that could be used to develop immunotherapies that tap NK cells to combat cancer...

journal_title：Cancer discovery

authors：

更新日期：2018-12-01 00:00:00

abstract：:In this issue of Cancer Discovery, Dominguez and colleagues identify diacylglycerol kinase alpha (DGKα), an enzyme that converts the membrane lipid diacylglycerol to phosphatidic acid, as a central node upstream of mTOR and other oncogenic pathways. Importantly, targeting DGKα causes apoptosis in cancer cells and tumo...

journal_title：Cancer discovery

authors： Bhat KP,Aldape K

更新日期：2013-07-01 00:00:00

abstract：:Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, g...

journal_title：Cancer discovery

authors： Clarke M,Mackay A,Ismer B,Pickles JC,Tatevossian RG,Newman S,Bale TA,Stoler I,Izquierdo E,Temelso S,Carvalho DM,Molinari V,Burford A,Howell L,Virasami A,Fairchild AR,Avery A,Chalker J,Kristiansen M,Haupfear K,Dalt

更新日期：2020-07-01 00:00:00

abstract：UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...

journal_title：Cancer discovery

authors： Stoeck A,Lejnine S,Truong A,Pan L,Wang H,Zang C,Yuan J,Ware C,MacLean J,Garrett-Engele PW,Kluk M,Laskey J,Haines BB,Moskaluk C,Zawel L,Fawell S,Gilliland G,Zhang T,Kremer BE,Knoechel B,Bernstein BE,Pear WS,Liu

更新日期：2014-10-01 00:00:00

abstract：:To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma in situ (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutro...

journal_title：Cancer discovery

authors： Gil Del Alcazar CR,Huh SJ,Ekram MB,Trinh A,Liu LL,Beca F,Zi X,Kwak M,Bergholtz H,Su Y,Ding L,Russnes HG,Richardson AL,Babski K,Min Hui Kim E,McDonnell CH 3rd,Wagner J,Rowberry R,Freeman GJ,Dillon D,Sorlie T,Cous

更新日期：2017-10-01 00:00:00

abstract：:mTOR inhibition with the ATP-competitive kinase inhibitor AZD8055 induces receptor tyrosine kinase-dependent feedback activation of AKT. ...

journal_title：Cancer discovery

authors： Keniry M,Parsons R

更新日期：2011-08-01 00:00:00

abstract：:In this issue of Cancer Discovery, Auciello and colleagues find that in the pancreatic cancer microenvironment activated fibroblasts secrete specific lipids that provide a source of biomass production and signaling molecules for cancer cells, fueling their proliferation and migration. Targeting of this stromal-tumor m...

journal_title：Cancer discovery

authors： Biffi G,Tuveson DA

更新日期：2019-05-01 00:00:00

abstract：:Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG-dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX...

journal_title：Cancer discovery

authors： Liao C,Zhang Y,Fan C,Herring LE,Liu J,Locasale JW,Takada M,Zhou J,Zurlo G,Hu L,Simon JM,Ptacek TS,Andrianov VG,Loza E,Peng Y,Yang H,Perou CM,Zhang Q

更新日期：2020-11-01 00:00:00

abstract：:The TKI avapritinib showed preliminary evidence of efficacy in gastrointestinal stromal tumors. ...

journal_title：Cancer discovery

authors：

更新日期：2020-09-01 00:00:00

abstract：:Domchek and colleagues provide a case report of a 28-year-old woman with congenital abnormalities, inherited ovarian cancer, and carboplatin hypersensitivity. Interestingly, the woman had validated germline mutations in both BRCA1 alleles. These findings further implicate BRCA1 in the Fanconi anemia/BRCA pathway and h...

journal_title：Cancer discovery

authors： D'Andrea AD

更新日期：2013-04-01 00:00:00

abstract：:It is possible to decipher the clonal architecture of a tumor and the sequence in which cancer clones acquire genomic alterations through multiregion sequencing (M-seq). Serial evaluation of tumor specimens through M-seq can provide valuable information on the molecular basis of resistance to therapy. ...

journal_title：Cancer discovery

authors： Devarakonda S,Govindan R

更新日期：2015-08-01 00:00:00